연구성과로 돌아가기
2021 연구성과별 연구자 정보 (1352 / 2991)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Malignant potential of small pancreatic neuroendocrine neoplasm and its risk factors: A multicenter nationwide study | Kim, Yong-Tae | Kim, YT | 17 | 교신저자 | Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Liver Res Inst, Seoul, South Korea | CKE-7709-2022 | Kim, Yong Tae | yongtkim@snu.ac.kr;jhcho9328@yuhs.ac; | ||
| Malignant potential of small pancreatic neuroendocrine neoplasm and its risk factors: A multicenter nationwide study | Cho, Jae Hee | Cho, JH | 18 | 교신저자 | Yonsei Univ, Gangnam Severance Hosp, Dept Internal Med, Coll Med, Seoul, South Korea | AAL-8192-2020 | Cho, Jae Hee | 0000-0003-4174-0091 | Cho, Jae Hee | yongtkim@snu.ac.kr;jhcho9328@yuhs.ac; |
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | Ravandi, Farhad | Ravandi, F | 1 | 교신저자 | Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd, Houston, TX 77030 USA | GOH-3538-2022 | Ravandi, Farhad | 0000-0002-7621-377X | Ravandi, Farhad | fravandi@mdanderson.org; |
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | Roboz, Gail J. | Roboz, GJ | 2 | Weill Cornell Med, New York, NY USA | fravandi@mdanderson.org; | |||||
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | Roboz, Gail J. | Roboz, GJ | 2 | NewYork Presbyterian Hosp, New York, NY USA | fravandi@mdanderson.org; | |||||
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | Wei, Andrew H. | Wei, AH | 3 | Alfred Hosp, Dept Clin Haematol, Melbourne, Vic, Australia | F-3707-2012 | Wei, Andrew | 0000-0002-7514-3298 | Wei, Andrew | fravandi@mdanderson.org; | |
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | Wei, Andrew H. | Wei, AH | 3 | Mona Sh Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia | F-3707-2012 | Wei, Andrew | 0000-0002-7514-3298 | Wei, Andrew | fravandi@mdanderson.org; | |
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | Dohner, Hartmut | Döhner, H | 4 | Ulm Univ Hosp, Dept Internal Med 3, Ulm, Germany | C-8933-2016 | Döhner, Hartmut | fravandi@mdanderson.org; | |||
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | Pocock, Christopher | Pocock, C | 5 | Kent & Canterbury Hosp, Canterbury, Kent, England | fravandi@mdanderson.org; | |||||
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | Selleslag, Dominik | Selleslag, D | 6 | AZ Sint Jan Brugge Oostende AV, Brugge, Belgium | fravandi@mdanderson.org; | |||||
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | Montesinos, Pau | Montesinos, P | 7 | Hosp Univ & Politecn La Fe, Valencia, Spain | GYU-2673-2022 | Montesinos, Pau | 0000-0002-3275-5593 | Montesinos, Pau | fravandi@mdanderson.org; | |
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | Sayar, Hamid | Sayar, H | 8 | Indiana Univ, Canc Ctr, Indianapolis, IN USA | fravandi@mdanderson.org; | |||||
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | Musso, Maurizio | Musso, M | 9 | La Maddalena Casa Cura, Palermo, Italy | fravandi@mdanderson.org; | |||||
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | Figuera-Alvarez, Angela | Figuera-Alvarez, A | 10 | Hosp Univ La Princesa, Madrid, Spain | fravandi@mdanderson.org; | |||||
| Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | Safah, Hana | Safah, H | 11 | Tulane Univ, Hlth Sci Ctr, New Orleans, LA USA | fravandi@mdanderson.org; |
페이지 이동: